Phase II/III Trial evaluating palovarotene in the patients with multiple osteochondromas (MO)

Trial Profile

Phase II/III Trial evaluating palovarotene in the patients with multiple osteochondromas (MO)

Planning
Phase of Trial: Phase II/III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Bone cancer
  • Focus Therapeutic Use
  • Acronyms MO-Ped
  • Most Recent Events

    • 20 Nov 2017 New trial record
    • 13 Nov 2017 According to a Clementia Pharmaceuticals media release, Company has received regulatory feedback on the protocol for its Phase II/III MO-Ped study of palovarotene for the treatment of patients with MO, and expects to enroll the first patient in this global study by early 2018.
    • 13 Nov 2017 According to a Clementia Pharmaceuticals media release, this trial expected to begin in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top